Sentences with phrase «leader at the cancer»

Not exact matches

The company was founded in 2010 by Dr. Luis Diaz and Dr. Victor Velculescu, leaders in cancer genomics at Johns Hopkins School of Medicine.

Matt was kind enough to post an update on my own condition a few days ago, and I can think of at least 5 other bloggers and leaders I have become aware of in the last couple of weeks who are battling cancer.

Former Senate Majority Leader Harry Reid, is currently being treated for pancreatic cancer at Johns Hopkins Hospital in Baltimore.

New Yorkers will have greater access to breast cancer screenings at hospitals and insurance co-payments for all mammograms will be eliminated under an agreement Cuomo and the state Legislature's leaders announced yesterday.

Complicating matters further for Senate Republicans is the condition of their deputy majority leader, Tom Libous: The Binghamton Republican, already undergoing treatments for terminal cancer, faces a charge of lying to the FBI in case revolving around his son's employment at a politically connected law firm.

NYC Mayor Bill de Blasio traveled through Paris yesterday, laying wreaths at the sites of the recent terror attacks, meeting with dignitaries and Jewish community leaders and, as the mayor of a city with a prominent Jewish population, speaking about «the cancer of anti-Semitism» throughout the world.

The deals he and the legislative leaders struck earlier this week included a package of efforts to combat opioid and heroin addiction, a growing scourge across the state; a push to expand access to mammograms and other methods of breast - cancer detection; and an agreement on improving safety at rail crossings, which carried all the political excitement of, well, rail crossings.

ALBANY, N.Y. — New Yorkers will have greater access to breast cancer screenings at hospitals and insurance co-payments for all mammograms will be eliminated under an agreement Gov. Andrew Cuomo and the state Legislature's leaders announced Sunday.

Last summer, a number of LGBT leaders ---- including Dr. Marjorie Hill, CEO of Gay Men's Health Crisis, Liz Margolies, executive director of the National LGBT Cancer Network, Melissa Goodman, an LGBT and reproductive rights attorney at the New York Civil Liberties Union, and Amber Hollibaugh, the co-director of Queers for Economic Justice ---- told Gay City News they were strong backers of paid sick leave.

Moreno was pulled back to Spain in 2005 by a 5 - year junior - leader position at the Spanish National Cancer Research Centre (CNIO) in Madrid.

Co-Senior author, Dr Florence Raynaud, a group leader at The Institute of Cancer Research, London, said: «The study made accurate measurements of a large number of metabolites as they varied by time of day and under different sleep patterns.

Study leader Professor Janet Shipley, Professor of Cancer Molecular Pathology at The Institute of Cancer Research, London, said:

«Prostate cancers only kill men after they have spread or «metastasised» from the prostate,» says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men's Health.

This discovery, and the clinical trials we have underway, suggest that RB status might be used as means to stratify patients into more effective treatment regimens,» said William Kevin Kelly, leader of the Prostate Cancer Program at SKCC.

«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic Research and the Program Leader for Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel Cancer Center at Jefferson Health.

BARCELONA, SPAIN — Many factors influence success in a science career, including hard work, tenacity, flair, and luck, and all of them have played a role in the success of Nobel laureate Tim Hunt, who today is a group leader emeritus at the Cancer Research UK London Research Institute.

«Dendritic cells are essential for prompting the immune response against malignant cells and for driving the clinical success of cancer immunotherapy, but their function is often defective in cancer patients,» said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment & Metastasis Program at Wistar.

University of Calgary researchers including Luchman, Weiss and Dr. Greg Cairncross — director of SACRI, and leader of the Terry Fox Research Institute (TFRI) «Therapeutic Targeting of Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblacancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblaCancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblastoma.

Biden will talk about his plan this afternoon at the White House before attending an event featuring several cancer research and advocacy leaders.

«The findings of both studies support a growing body of research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stcancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both studies.

«Those studies revealed new insights into how cancer might spread, but they didn't necessarily show what is happening in patients,» said study leader Maja Oktay, M.D., Ph.D., associate professor of pathology at Albert Einstein College of Medicine of Yeshiva University and attending cytopathologist at Montefiore.

«What we found astonished us,» says study leader Andrew Feinberg, M.D., Bloomberg Distinguished Professor of Epigenetics at The Johns Hopkins University and a Johns Hopkins Kimmel Cancer Center member.

«Even when the genes driving cancer are known, clinicians don't have an efficient way to choose among the hundreds of possible drug therapies,» said study leader Kai Wang, PhD, associate professor of biomedical informatics and director of clinical informatics at the Institute for Genomic Medicine at CUMC.

For the system to work well, you have to do it,» says Eduardo Moreno, a junior group leader at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain.

Lead author Dr Chris Bakal, leader of the Dynamical Cell Systems Team at The Institute of Cancer Research, London, said: «The endoplasmic reticulum is the factory of our cells, creating the proteins and lipids needed for our cells to grow and proliferate.

Study leader Fausto J. Rodriguez, M.D., associate professor of pathology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center, says the new study sought to sort out what makes the more aggressive NF1 - related tumors genetically different from low grade tumors and normal, healthy cells.

«Ovarian cancer treatments have not changed much in many decades, and this may be, in part, because we have been studying the wrong tissue of origin for these cancers,» says study leader Victor Velculescu, M.D., Ph.D., a professor of oncology at the Johns Hopkins Kimmel Cancer Ccancer treatments have not changed much in many decades, and this may be, in part, because we have been studying the wrong tissue of origin for these cancers,» says study leader Victor Velculescu, M.D., Ph.D., a professor of oncology at the Johns Hopkins Kimmel Cancer CCancer Center.

If the tumor is large or there's obvious evidence that the cancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer Instcancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer InstCancer Institute.

Study leader Dr Nicholas Turner, Team Leader in Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust,leader Dr Nicholas Turner, Team Leader in Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust,Leader in Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

«Checkpoint inhibitors are one of the most exciting recent advances for cancers, but the mechanism by which most patients become resistant to these therapies has been a mystery,» says Victor E. Velculescu, M.D., Ph.D., program leader in the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and professor of oncology.

«We identified a number of new genes that are frequently mutated in CS,» said senior author Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, and program leader of the gynecological cancers research program at Smilow Cancer Hospital at Yale - New Haven and a member of Yale Cancer Center.

Senior study author Dr Edward Morris, Team Leader in Structural Electron Microscopy at The Institute of Cancer Research, London, said:

Study leader Professor Nazneen Rahman, Head of Genetics and Epidemiology at The Institute of Cancer Research, London, and Head of Cancer Genetics at The Royal Marsden NHS Foundation Trust, said: «This research adds further evidence that malfunctioning of the PAF1 complex can lead to cCancer Research, London, and Head of Cancer Genetics at The Royal Marsden NHS Foundation Trust, said: «This research adds further evidence that malfunctioning of the PAF1 complex can lead to cCancer Genetics at The Royal Marsden NHS Foundation Trust, said: «This research adds further evidence that malfunctioning of the PAF1 complex can lead to cancercancer.

That's given us the parts list,» said study co-senior author William Hahn, an institute member in the Broad Cancer Program, chief of the Division of Molecular and Cellular Oncology at Dana - Farber, and a leader in the Cancer Dependency Map initiative, a joint effort spanning the Broad Institute and Dana - Farber.

PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international leader in biomedical research in the fields of cancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (Mcancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MCancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

Lead author Dr Nicola Valeri, Leader of the Gastrointestinal Cancer Biology and Genomics Team at The Institute of Cancer Research, London, said:

Perrakis is a researcher and group leader at the Netherlands Cancer Institute and an expert in unravelling cancer proCancer Institute and an expert in unravelling cancer procancer proteins.

The program will feature Olufunmilayo Olopade, MD, FACP, an international leader in breast cancer research and director of the Cancer Risk Clinic at the University of Chicago Medical Ccancer research and director of the Cancer Risk Clinic at the University of Chicago Medical CCancer Risk Clinic at the University of Chicago Medical Center.

«Our findings are doubly important,» said study leader Antonio Iavarone, MD, professor of pathology and neurology at CUMC, and a member of the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork - Presbyterian Hospital / Columbia University Medical Center.

This year's Action Award honorees include global leaders in the fight to end cancer as we know it; a world leader in advancing the emerging field of regenerative medicine and game - changing cell therapy medical treatments; the president of a non-profit group focused on developing cures for chronic, debilitating and fatal diseases; a sickle cell and stem cell advocate and founder / science administrator of the Axis Advocacy; and the founding director of the Institute for Integrated Cell - Material Sciences (iCeMS) at Japan's Kyoto University.

Study co-author Laura van't Veer, a molecular biologist and leader of the breast oncology program at the Helen Diller Family Comprehensive Cancer Center at the University of California at San Francisco, did the research that led to the gene test while working for the Netherlands Cancer Institute.

LA JOLLA, CA — Renato Dulbecco, M.D., Nobel Prize winner and a global leader in cancer research passed away February 19 at his home in La Jolla.

Agilent Technologies has presented its latest Thought Leader Award to Rohit Bhargava, founder professor of bioengineering at the University of Illinois Cancer Center in Urbana - Champaign, US.

The New Investigator Committee has a broad remit spanning basic and translational cancer research, responsible for a number of funding schemes to support the cancer research leaders of tomorrow at all stages of their careers.

Study leader Professor Nazneen Rahman, Head of Cancer Genetics at The Institute of Cancer Research, London, and The Royal Marsden Hospital Foundation Trust, said: «DECoN has transformed our gene testing pipeline, making it more efficient and more effective, whilst also making it much faster and cheaper.

The workshop was attended by lab directors and supervisors from the National Cancer Institute and focused on providing a core set of skills for emerging leaders at the NCI.

At this year's conference Ms. Leach, cancer genetic counselor work leader at CPGH, presided as CGA PresidenAt this year's conference Ms. Leach, cancer genetic counselor work leader at CPGH, presided as CGA Presidenat CPGH, presided as CGA President.

She is a member of the Department of Pathology at Brigham and Women's Hospital, an Associate Member at the Broad Institute of MIT and Harvard, and Leader of the Cancer Immunology Program at the Dana - Farber / Harvard Cancer Center.

He was the Program Leader of the Hepato - Pancreato - Biliary Cancer Program at the University of South Alabama before being recruited to Vanderbilt.

Sylvester's cancer specialists are leaders in the use of a variety of cutting - edge diagnostic procedures that help detect cancers at their earliest stages.